Login to Your Account



Sangamo Biosciences Prices its $65M Public Offering

By Catherine Shaffer
Staff Writer

Thursday, September 19, 2013
Sangamo Biosciences Inc. will collect about $65 million in gross proceeds from a public offering of 6. 1 million shares of common stock in an underwritten public offering. The company will funnel the money into continued research and development of its engineered zinc finger DNA-binding proteins (ZFP).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription